{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
nonoxynol-9
to a specific field?
Class (Stereo):
CHEMICAL (ACHIRAL)
Etoformin is an antidiabetic drug. It decreases gluconeogenesis and increases peripheral utilization of glucose.
Class (Stereo):
CHEMICAL (RACEMIC)
Conditions:
Binospirone (MDL-73,005-EF) acts as a potent, highly selective 5-HT1A ligand: as an antagonist at postsynaptic 5-HT1A receptors and also acts as a highly efficacious partial agonist at somatodendritic autoreceptors. Experiments on rodents have shown, that it also possesses anxiolytic properties.
Class (Stereo):
CHEMICAL (RACEMIC)
Prizidilol (also known as SKF 92657) is arylpyridazinylhydrazine derivative patented by Smith Kline and French Laboratories Ltd. as an antihypertensive agent. In clinical trials, Supine and standing blood pressure measured 24--27 h after drug intake was reduced Slight but significant decreases in heart rate were seen after moderate doses of prizidilol. A more pronounced blood pressure reduction was noticed 2--7 h after drug administration. Prizidilol was well tolerated, although dizziness and tiredness were reported by four patients and edema by two.
Class (Stereo):
CHEMICAL (RACEMIC)
FLESTOLOL is an ultra-short-acting beta-adrenergic blocking agent without any intrinsic sympathomimetic activity.
Status:
Investigational
Source:
NCT00526968: Phase 1 Interventional Completed Human Volunteers
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Adrogolide is a chemically stable prodrug of the dopamine D1 receptor agonist A-86929. Adrogolide is rapidly converted in plasma to A-86929. A-86929 has high affinity and functional selectivity for the dopamine D1 receptor. Adrogolide has been in phase II clinical trials for the treatment of Parkinson's disease and cocaine abuse. However, this research has been discontinued. The adverse events associated with its use of adrogolide were of mild-to-moderate severity and included injection site reaction, asthenia, headache, nausea, vomiting, postural hypotension, vasodilitation, and dizziness.
Status:
Investigational
Source:
INN:sibopirdine [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Sibopirdine (EXP921) is a cognition enhancing agent structurally related to linopirdine that was in preclinical development with Bristol-Myers Squibb in the USA as a treatment of Alzheimer's disease. EXP921 was a potential drug candidate for the improvement of cognitive performance in patients with Alzheimer's-type dementia. It has been shown to improve cognitive performance in rodent and primate models of learning and memory. EXP921 was observed to increase the depolarization induced release of acetylcholine, dopamine, and, to a lesser extent, serotonin using slices from the rat cerebral cortex, hippocampus, and caudate nucleus.
Status:
Investigational
Source:
NCT00519662: Phase 1 Interventional Completed Advanced Solid Tumors
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
SNS 314 is a selective small molecule inhibitor of Aurora kinases A, B and C. The compound was being developed by Sunesis Pharmaceuticals for the treatment of cancer. Proliferating cells treated with SNS-314 bypass the mitotic spindle checkpoint and fail to undergo cytokinesis, leading to multiple rounds of endoreduplication and eventually cell death. SNS-314 inhibits tumor growth in a variety of preclinical models, and it was being tested in single agent Phase 1 studies in patients with advanced solid tumours.
Status:
Investigational
Source:
INN:methiomeprazine [INN]
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Oxamarin was developed as a hemostatic agent. Information about the current use of this compound is not available.
